Orient EuroPharma Co., Ltd. has announced that it has signed an exclusive sales and marketing agreement for the new AIDS drug Trogarzo in Taiwan with Taimed Biologics. Starting and ending dates (or rescission date) of the contract or commitment: May 20th, 2024. Major content (not applicable where rescinded): Orient EuroPharma (OEP) and TaiMed Biologics officially signed an exclusive license agreement for the HIV drug Trogarzo in Taiwan.

The relevant partnering agreement will not be disclosed due to mutual confidentiality. Under the agreement, OEP shall pursue regulatory approval, subsequent promotion, and commercial sales of the Product in the above-agreed territory. Any other important agreement (not applicable where rescinded): This agreement grants exclusivity to OEP for the territory of Taiwan.

Effect on company finances and business: Increase revenue. Concrete purpose/objective: Expand the product line for sales. The contribution of this sales agreement to the company's future revenue will depend on the actual business development needs of the client.

Investors should make rational judgments and invest prudently.